Sonja C. Bernhard
University of Basel
5 Papers
Sonja C. Bernhard is an academic researcher from University of Basel. The author has contributed to research in topics: African trypanosomiasis & Medicine. The author has an hindex of 3, co-authored 3 publications. Previous affiliations of Sonja C. Bernhard include Swiss Tropical and Public Health Institute.
Chat about Author
Papers
Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial
Victor Kande Betu Ku Mesu,Wilfried Mutombo Kalonji,Clélia Bardonneau,Olaf Valverde Mordt,Séverine Blesson,François Simon,Sophie Delhomme,Sonja C. Bernhard,Willy Kuziena,Jean Pierre Fina Lubaki,Steven Lumeya Vuvu,Pathou Nganzobo Ngima,Hélène Mahenzi Mbembo,Medard Ilunga,Augustin Kasongo Bonama,Josué Amici Heradi,Jean Louis Lumaliza Solomo,Guylain Mandula,Lewis Kaninda Badibabi,Francis Regongbenga Dama,Papy Kavunga Lukula,Digas Ngolo Tete,Crispin Lumbala,Bruno Scherrer,Nathalie Strub-Wourgaft,Antoine Tarral +25 more
TL;DR: The findings show that oral fexinidazole is effective and safe for the treatment of Tpanosoma brucei gambiense infection compared with nifurtimox eflornithine combination therapy in patients with late-stage g-HAT.
236
Fexinidazole for Human African Trypanosomiasis, the Fruit of a Successful Public-Private Partnership
TL;DR: The history of drug discovery for HAT is reviewed with special emphasis on the discovery, pre-clinical development, and operational challenges of the clinical trials of fexinidazole, which greatly facilitates the diagnosis and treatment algorithm for gHAT, increasing the attainable coverage and paving the way towards the envisaged goal of zero transmission by 2030.
29
Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies.
Christian Burri,Christian Burri,Patrick Yeramian,James L. Allen,A Merolle,Kazadi Kyanza Serge,Alain Mpanya,Pascal Lutumba,Victor Kande Betu Ku Mesu,Constantin Miaka Mia Bilenge,Jean Pierre Fina Lubaki,Alfred Mpoo Mpoto,Mark E. Thompson,Blaise Fungula Munungu,Francisco Manuel,Théophilo Josenando,Sonja C. Bernhard,Sonja C. Bernhard,Carol A. Olson,Johannes Blum,Johannes Blum,Richard R. Tidwell,Gabriele Pohlig,Gabriele Pohlig +23 more
TL;DR: Pafuramidine for the treatment of first stage HAT was comparable in efficacy to pentamidine after 10 days of dosing, and results support continuation of the development program for pafur amidine into Phase 3.
Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2–3 trial
Victor Kande Betu Kumesu,Wilfried Mutombo Kalonji,Clélia Bardonneau,Olaf Valverde Mordt,Digas Ngolo Tete,Séverine Blesson,François Simon,Sophie Delhomme,Sonja C. Bernhard,Pathou Nganzobo Ngima,Hélène Mahenzi Mbembo,Jean-Pierre Fina Lubaki,Steven Lumeya Vuvu,Willy Kuziena Mindele,Médard Ilunga Wa Kyhi,Guylain Mandula Mokenge,Lewis Kaninda Badibabi,Augustin Kasongo Bonama,Papy Kavunga Lukula,Crispin Lumbala,Bruno Barros Scherrer,Nathalie Strub-Wourgaft,Antoine Tarral +22 more
TL;DR: Fexinidazole has been reported as an effective oral monotherapy against non-severe gambiense human African trypanosomiasis in a recent trial in adults as mentioned in this paper .
Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial.
Gabriele Pohlig,Sonja C. Bernhard,Sonja C. Bernhard,Johannes Blum,Christian Burri,Christian Burri,Alain Mpanya,Jean Pierre Fina Lubaki,Alfred Mpoo Mpoto,Blaise Fungula Munungu,Patrick Mangoni N’tombe,Gratias Kambau Manesa Deo,Pierre Nsele Mutantu,Florent Mbo Kuikumbi,Alain Fukinsia Mintwo,Augustin Kayeye Munungi,Amadeu Dala,Stephen Macharia,Constantin Miaka Mia Bilenge,Victor Kande Betu Ku Mesu,José R. Franco,Ndinga Dieyi Dituvanga,Richard R. Tidwell,Carol A. Olson +23 more
TL;DR: Pafuramidine was non-inferior to pentamidine as the upper bound of the 95% confidence interval did not exceed 15%; however, 3 patients in the pafur amidine group had glomerulonephritis or nephropathy approximately 8 weeks post-treatment.